The new system developed by Professor Chad Mirkin delivers CRISPR machinery more safely and effectively into cells.

91%客观缓解率的背后，是CRISPR基因编辑技术对免疫细胞"同族相残"魔咒的彻底打破 在全球细胞治疗领域因CAR-T在B细胞血液肿瘤中的成功而欢呼时，一个顽固的堡垒依然久攻不下——T细胞恶性肿瘤。当患者自身的T细胞已成为“叛军”，如何再用它们制造“平叛军队”？即使造出军队，它们是否会在执行任务前就“自相残杀”？ 美国生物科技公司Wugen用一项突破性的技术设计和1.15亿美元的最新融资，给出了自 ...

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapie ...

This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading ...

As the government fumbled Covid-19 testing, researchers at UC Berkeley's Innovative Genomics Institute stepped up—with their own time and funding.

Researchers used evolutionary genetics and CRISPR gene editing tech to develop an innovative treatment for gout. The approach ...

First Phase I clinical trial data with CRISPR-engineered T cells suggest the approach is feasible and safe, with the T cells persisting for months.

CRISPR will also allow us to act more boldly in the face of other important, interconnected issues such as food security, environmental sustainability and social inequality.

Researchers are starting to harness the potential of this much-hyped gene editing technique – with coming applications in medicine, biology and agriculture.